Actively Recruiting
Transcranial Magnetic Stimulation (TMS) Effects Using Magnetoencephalography (MEG) Study
Led by Wake Forest University Health Sciences · Updated on 2026-04-17
10
Participants Needed
1
Research Sites
92 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Alcohol use disorder (AUD) is a complex chronic brain disease characterized by compulsive alcohol use, loss of control over drinking, and negative emotional states. Extensive research has identified the general neural circuitry underlying AUD. There is an exciting opportunity to intervene in AUD using neuromodulation. Transcranial magnetic stimulation (TMS) offers a non-invasive method to modulate brain activity, making it a promising tool for investigating, modulating, and potentially treating AUD. However, the precise effects of TMS on neural circuits involved in AUD and the mechanisms underlying these effects must first be understood. Magnetoencephalography (MEG) is a neuroimaging method that provides direct measurement of brain activity within neural circuits with high temporal resolution. Critically, MEG can measure brain activity in a wide range of frequencies that are consistent with those targeted by TMS. The goal of this proposal is therefore to collect preliminary and feasibility data to support a future NIH grant application that would use MEG to investigate TMS effects in individuals with AUD (iAUD).
CONDITIONS
Official Title
Transcranial Magnetic Stimulation (TMS) Effects Using Magnetoencephalography (MEG) Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants aged 21 to 65 years
- Non-AUD participants must have a DSM-5 score for AUD of 0
- Non-AUD participants must have an AUDIT score of 7 or less
- Non-AUD participants must not be heavy alcohol consumers
- AUD participants must have a DSM-5 score for AUD of 3 or higher
- AUD participants must have an AUDIT score of 8 or higher
- AUD participants must be heavy alcohol consumers
You will not qualify if you...
- Current substance use disorder other than alcohol use disorder or frequent use of non-prescribed psychoactive substances
- Current serious psychiatric disorder or any history of a psychotic disorder
- Any health problem that could interfere with or be worsened by study procedures (e.g., migraines, claustrophobia)
- Currently taking or starting medications that affect alcohol intake or craving
- History of traumatic brain injury causing hospitalization or loss of consciousness, or history of brain hemorrhage
- Does not meet safety criteria for TMS or MRI
- Females of childbearing potential who are pregnant, nursing, planning pregnancy, or not using reliable birth control
- Elevated seizure risk due to history or medications
- Clinical Intake Withdrawal Assessment score greater than 5
- Unable to read or understand questionnaires, assessments, or informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States, 27157
Actively Recruiting
Research Team
M
Merideth A Addicott, PhD
CONTACT
M
Michiyah Kimber
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
BASIC_SCIENCE
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here